Last reviewed · How we verify
calcipotriol
At a glance
| Generic name | calcipotriol |
|---|---|
| Also known as | Dovonex Cream (50 mcg/g 0.005%), Platelet Rich Plasma, Dovonex, Calcipotriol 0.005%, calcipoheal |
| Sponsor | NeoStrata Company, Inc. |
| Target | Vitamin D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Plaque psoriasis
- Scalp psoriasis
Common side effects
Key clinical trials
- Comparison of Topical Photodynamic Therapy With Topical Calcipotriol in Management of Oral Leukoplakia (PHASE3)
- Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata (PHASE4)
- Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis. (PHASE2)
- Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis (PHASE4)
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart (NA)
- 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- calcipotriol CI brief — competitive landscape report
- calcipotriol updates RSS · CI watch RSS
- NeoStrata Company, Inc. portfolio CI